Sweden’s National Council for Medical Technology (NT-rådet) has reversed its previous decision and now recommends Tofersen, a new drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). This marks a significant shift, potentially offering a new therapeutic option for ALS patients. The recommendation follows a re-evaluation of the drug’s benefits and cost-effectiveness. Tofersen is designed to slow the progression of ALS in specific patient groups. Previously, the council had not recommended the drug, citing concerns over its price and limited evidence of benefit. The reversal indicates new data or considerations influenced the council’s assessment, offering hope for improved patient outcomes. Further details regarding access and implementation are expected to be announced soon.